Market Data
CELHA: ÇELİK HALAT VE TEL SANAYİİ A.Ş. Stock Live Price Graph
Company profile
Market News & Analysis
Target Price
No analyst target price data is available for this instrument.
Dividend History
Cash dividends
| Payment | Gross / share | Net / share | Yield | Per 1,000 TRY |
|---|---|---|---|---|
| Mar 24, 2026 | TRY 0 | TRY 0 | 0% | TRY 0 |
| Mar 2, 2025 | TRY 0 | TRY 0 | 0% | TRY 0 |
Splits & capital actions
| Date | Ratio | Bonus % | Rights % | Dividend % |
|---|---|---|---|---|
| Mar 1, 2026 | 1 | 0% | 0% | 0% |
| Jul 23, 2025 | 2.78444 | 0% | 196.93221% | 0% |
| Aug 21, 2024 | 1 | 0% | 0% | 0% |
| Jan 24, 2024 | 1.96027 | 0% | 100% | 0% |
| Apr 28, 2022 | 1.01541 | 0% | 0% | 12.077% |
| Feb 14, 2021 | 2.35446 | 0% | 151.5152% | 0% |
| Apr 29, 2019 | 1.11052 | 0% | 0% | 60.606% |
| Apr 17, 2018 | 1.03751 | 0% | 0% | 32% |
| May 9, 2017 | 1.02029 | 0% | 0% | 7% |
| May 14, 2015 | 1.06557 | 0% | 0% | 20% |
| Jul 19, 2009 | 1.10145 | 10% | 0% | 0% |
| Mar 30, 2008 | 2.01563 | 101.6% | 0% | 0% |
| Jul 17, 2003 | 1.24696 | 24.696% | 0% | 0% |
| Mar 24, 2003 | 1.5 | 50% | 0% | 0% |
| Sep 9, 2002 | 2 | 100% | 0% | 0% |
| Jul 24, 2000 | 2 | 100% | 0% | 0% |
| May 30, 1999 | 1.04 | 0% | 0% | 24% |
| May 31, 1998 | 1.04 | 0% | 0% | 45% |
| Jun 17, 1997 | 1.85 | 85% | 0% | 0% |
What Is CELHA? Live CELHA Prices and Analysis
CELHA, or Celularity Inc., is a biotechnology company focused on developing innovative cell-based therapies to treat various diseases. The company specializes in harnessing the power of human cells, particularly placental-derived cells, to create treatments that are safe, effective, and can potentially revolutionize the medical landscape. Investors closely follow CELHA due to its unique position in the biotechnology sector, the promising nature of its products, and its potential for significant returns.
As a part of the biotechnology industry, CELHA's developments are crucial not only for the company's growth but also for the broader implications they may have on healthcare. The increasing demand for advanced medical treatments and therapies has made companies like Celularity Inc. a focal point for investors looking to capitalize on the future of medicine.
Market Context
The biotechnology sector has seen a surge in interest, especially in the wake of recent advancements in cell therapies and personalized medicine. CELHA operates within this dynamic environment, where international trading is influenced by regulatory approvals, scientific breakthroughs, and market competition. The stock is primarily priced in U.S. dollars, and its volatility can be attributed to various external factors, including market sentiment, investor speculation, and broader economic indicators.
Why Do CELHA Prices Rise or Fall?
The price of CELHA shares can fluctuate based on multiple factors that influence investor perception and market dynamics. Understanding these factors is essential for making informed trading decisions.
- Clinical trial results: Positive or negative outcomes from clinical trials can significantly impact stock prices.
- Regulatory approvals: News regarding FDA approvals or denials can cause immediate price reactions.
- Market competition: The emergence of new competitors or advancements by rival companies can affect CELHA's market position.
- Partnerships and collaborations: Strategic alliances with other firms can bolster investor confidence and drive prices higher.
- Earnings reports: Quarterly earnings that exceed or fall short of expectations can lead to price volatility.
- Market sentiment: General market trends and investor sentiment towards biotechnology can heavily influence CELHA's stock performance.
- Economic conditions: Macro-economic factors such as interest rates, inflation, and global events can create uncertainty and affect stock prices.
- Technological advancements: Innovations in cell therapy or related technologies can enhance CELHA's prospects and attract investor interest.
Overall, the interplay of these factors contributes to the dynamic nature of CELHA's stock price, making it crucial for investors to stay informed.
Why Is Live CELHA Price Tracking Important?
Tracking the live price of CELHA is vital for investors for several reasons. Real-time data helps investors make quick decisions based on current market conditions and trends.
- Immediate access to price changes allows for timely buy or sell decisions.
- Monitoring price movements can reveal patterns that may indicate future trends.
- Staying updated on CELHA's price can help investors assess their portfolio performance.
- Live tracking can aid in identifying potential entry and exit points for trades.
- Real-time data provides insights into market sentiment, helping investors gauge overall interest in CELHA.
What Should You Consider When Trading / Investing in CELHA?
Investing in CELHA involves several considerations that can influence both risk and potential reward. Investors should be aware of the following:
- Risk tolerance: Understand your risk appetite, as biotechnology stocks can be highly volatile.
- Regulatory landscape: Keep abreast of regulatory changes that may impact CELHA's business operations.
- Market trends: Analyze broader trends in the biotechnology sector to gauge CELHA's market position.
- Earnings expectations: Pay attention to projected earnings and how they align with market forecasts.
- Volatility warnings: Be prepared for significant price swings, especially around clinical trial announcements.
What Can You Find on the Investvio CELHA Page?
- Live price updates for CELHA shares.
- Detailed charts displaying historical price movements.
- Technical analysis tools to evaluate stock performance.
- Latest news and updates related to CELHA and the biotechnology sector.
- Earnings reports and forecasts to assess company performance.
In conclusion, monitoring CELHA's stock performance is essential for investors looking to capitalize on opportunities in the rapidly evolving biotechnology sector. With the right tools and information available on Investvio, you can make informed decisions that align with your investment strategy.